Business
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)) (Study ID: K
About this update from Alphamab Oncology
[{"type":"text","content":"SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)) (Study ID: KN026-001, also known as KC-WISE), have been presented at the 2025 European Society for Medical Oncology Congress (ESMO Congress 2025) Late-Breaking Abstract (LBA) Oral Presentation Session.","length":739,"tagName":"p"},{"type":"text","content":"LBA Oral Presentation Session is a highly anticipated global highlight of the ESMO Congress. The research presented in this category is both highly topical and of significant clinical value. Their findings often herald potential impacts on current clinical practice and can even guide the future direction of entire therapeutic fields.","length":335,"tagName":"p"},{"type":"text","content":"Title ：KN026 in combination with chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Interim analysis of KC-WISENumber: LBA 78Speaker: Jianming Xu, Chinese PLA General HospitalDate：Friday, 17 October 2025","length":255,"tagName":"p"},{"type":"text","content":"METHODS","length":7,"tagName":"p","attribs":{}},{"type":"text","content":"Enrolled patients in study KN026-001 (KC-WISE) with HER2-positive GC/GEJ who had disease progression after trastuzumab-based therapy were randomized to receive either anbenitamab (KN026) in combination with chemotherapy (the "Anbenitamab Group") or chemotherapy with placebo (the "Control Group"). The patients were stratified based on (i) type of chemotherapy, (ii) HER2 expression level, and (iii) number of prior lines of treatments.","length":456,"tagName":"p"},{"type":"text","content":"RESULTS","length":7,"tagName":"p","attribs":{}},{"type":"text","content":"At baseline, patient characteristics were generally well balanced between the two groups. The median age was approximately 64 in the Anbenitamab Group and 61 in the Control Group. In both groups, over 80% of patients...